Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $633

Benzinga · 2d ago
Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $612 to $633.